Trial Protocol ID USOR 20417_D933LC00001_BEGONIA

Trial Description

A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

Contact us regarding Clinical Trials at or call us at 877-664-7724


  • Andrew Mener, M.D.

Disease Types


  • AstraZeneca NCT ID

  • NCT03742102